乳房健康市場機會、成長動力、產業趨勢分析及 2025 - 2034 年預測

2024 年全球乳房健康市場價值為 14 億美元，預計到 2034 年將以 5.9% 的複合年成長率成長，達到 25 億美元，這得益於人們對乳房疾病（尤其是乳腺炎）日益成長的擔憂，以及全球對乳製品的需求激增。隨著全球乳牛養殖規模的擴大和密集化，主動進行乳房健康管理比以往任何時候都更重要。乳房炎仍然是影響乳牛的最常見和最昂貴的疾病之一，會導致產奶量大幅下降、獸醫費用增加以及長期的牛群健康問題。農民更重視早期發現和預防，以保持獲利能力和動物福利。此外，全球對永續農業實踐的推動正在改變乳房健康市場，鼓勵採用傳統抗生素的替代品。

主要乳製品生產國的監管機構正在加強對抗菌藥物使用的管控，這進一步加速了對創新療法、疫苗、益生菌和免疫增強解決方案的需求。人工智慧驅動的健康監測、精準治療平台和先進的畜群管理系統等技術正在重塑農民處理乳房健康的方式。隨著消費者對符合道德採購且不含抗生素的乳製品的需求不斷成長，在技術創新、農業實踐不斷發展以及動物福利和食品安全意識不斷提高的共同推動下，未來十年市場將迎來強勁成長。

乳房炎是乳牛群中常見的疾病，持續推動對有效診斷、治療和預防解決方案的需求。隨著乳牛養殖業的密集程度不斷提高，標靶抗生素和非侵入性療法等新型治療方法正在開發，以最大限度地降低抗生素抗藥性。疫苗、益生菌和免疫療法領域的突破性進展，透過減少慢性感染和提高產奶量，顯著改善了牛群健康狀況。現代疫苗在預防乳房炎和其他乳房感染方面正變得非常有效，而益生菌和免疫刺激療法已被證明對於維持乳牛健康的微生物群至關重要。這些進步不僅提高了動物福利，還透過降低抗生素依賴促進了更永續的乳牛養殖。

市場細分為藥品和補充劑。 2023年，藥品市場收入達9.254億美元，這得益於乳房感染發病率的上升以及人們對抗生素抗藥性的擔憂加劇。人工智慧處方系統的日益普及，提高了治療的精確度和畜群的健康狀況，進一步支撐了藥品產業的成長。

就動物種類而言，乳牛在2024年佔據了85.4%的市場佔有率，佔據了市場主導地位。對早期診斷技術、遺傳學和抗病性的投資不斷增加，正在重塑畜群管理實踐。在全球抗生素限制措施的背景下，農民擴大採用益生菌和免疫療法藥物，而人工智慧驅動的監控和自動化擠奶系統也越來越受到青睞。

2024年，北美乳房健康市場佔全球收入的41%，預計2025年至2034年的複合年成長率將達到5.8%。美國強勁的牛奶產量推動了對先進乳房健康解決方案的需求，包括精密工具和永續管理策略。由美國食品藥物管理局（FDA）和美國農業部（USDA）主導的減少抗生素使用的監管措施，進一步推動了疫苗、益生菌和免疫刺激療法的普及。

全球乳房健康產業的主要參與者包括默克、BouMatic、AHV International、Albert Kerbl、勃林格殷格翰、詩華動物保健、藝康、禮來動物保健、利拉伐、G Shepherd 動物保健、維克和碩騰。這些公司正在投資創新療法以解決抗生素抗藥性問題，擴展人工智慧和自動化診斷能力，與獸醫診所和農民合作以提高產品採用率，並透過環保產品開發和農民教育計畫加強永續發展。

目錄

第1章：方法論與範圍

第2章：執行摘要

第3章：行業洞察

• 產業生態系統分析
• 產業衝擊力
  • 成長動力
    • 全球乳製品消費量和產量不斷成長
    • 提高對乳房健康管理的認知
    • 獸醫診斷和治療的進展
  • 產業陷阱與挑戰
    • 乳製品業抗生素使用的嚴格規定
    • 乳房健康治療和診斷成本高昂
• 成長潛力分析
• 監管格局
• 川普政府關稅
  • 對貿易的影響
    • 貿易量中斷
    • 報復措施
  • 對產業的影響
    • 供應方影響（原料）
      • 主要材料價格波動
      • 供應鏈重組
      • 生產成本影響
    • 需求面影響（售價）
      • 價格傳導至終端市場
      • 市佔率動態
      • 消費者反應模式
  • 受影響的主要公司
  • 策略產業反應
    • 供應鏈重組
    • 定價和產品策略
    • 政策參與
  • 展望與未來考慮
• 波特的分析
• PESTEL分析

第4章：競爭格局

• 介紹
• 公司矩陣分析
• 公司市佔率分析
• 主要市場參與者的競爭分析
• 競爭定位矩陣
• 策略儀表板

第5章：市場估計與預測：依產品類型，2021-2034

• 主要趨勢
• 製藥
  • 抗生素
  • 疫苗
  • 抗發炎藥物
  • 乳頭消毒劑
  • 乳房內輸注
  • 其他藥品
• 補充
  • 維生素和礦物質
  • 益生菌和益生元
  • 其他補充劑

第6章：市場估計與預測：依動物類型，2021-2034 年

• 主要趨勢
• 乳牛
• 其他動物類型

第7章：市場估計與預測：依疾病類型，2021-2034

• 主要趨勢
• 乳腺炎
  • 臨床乳腺炎
  • 亞臨床性乳腺炎
• 其他疾病類型

第 8 章：市場估計與預測：按配銷通路，2021-2034 年

• 主要趨勢
• 獸醫院藥房
• 零售藥局
• 其他分銷管道

第9章：市場估計與預測：按地區，2021-2034

• 主要趨勢
• 北美洲
  • 美國
  • 加拿大
• 歐洲
  • 德國
  • 英國
  • 法國
  • 西班牙
  • 義大利
  • 荷蘭
• 亞太地區
  • 中國
  • 日本
  • 印度
  • 澳洲
  • 韓國
• 拉丁美洲
  • 巴西
  • 墨西哥
  • 阿根廷
• 中東和非洲
  • 南非
  • 沙烏地阿拉伯
  • 阿拉伯聯合大公國

第10章：公司簡介

• AHV International
• Albert Kerbl
• Boehringer Ingelheim
• BouMatic
• Ceva Sante Animale
• DeLaval
• Ecolab
• Elanco Animal Health
• G Shepherd Animal Health
• Merck
• Virbac
• Zoetis

The Global Udder Health Market was valued at USD 1.4 billion in 2024 and is estimated to grow at a CAGR of 5.9% to reach USD 2.5 billion by 2034, driven by rising concerns over udder diseases, especially mastitis, along with the surging global demand for dairy products. As dairy farming operations expand and intensify worldwide, the importance of proactive udder health management is becoming more critical than ever. Mastitis remains one of the most common and costly diseases affecting dairy cows, leading to significant losses in milk production, increased veterinary expenses, and long-term herd health issues. Farmers are focusing more on early detection and prevention to maintain profitability and animal welfare. Moreover, the global push for sustainable farming practices is transforming the udder health market, encouraging the adoption of alternatives to traditional antibiotics.

Regulatory bodies across major dairy-producing nations are enforcing stricter controls on antimicrobial use, further accelerating the demand for innovative treatments, vaccines, probiotics, and immune-boosting solutions. Technologies such as AI-driven health monitoring, precision treatment platforms, and advanced herd management systems are reshaping how farmers approach udder health. With consumer demand rising for ethically sourced and antibiotic-free dairy products, the market is set to experience robust growth over the next decade, supported by a combination of technological innovations, evolving farming practices, and increasing awareness about animal welfare and food safety.

Mastitis, a frequent concern in dairy herds, continues to drive demand for effective diagnostic, therapeutic, and preventive solutions. As dairy farming grows more intensive, new treatments such as targeted antibiotics and non-invasive therapies are being developed to minimize antimicrobial resistance. Breakthroughs in vaccines, probiotics, and immunotherapies are significantly improving herd health by reducing chronic infections and boosting milk yields. Modern vaccines are becoming highly effective at preventing mastitis and other udder infections, while probiotics and immune-stimulant therapies are proving crucial for maintaining a healthy microbiome in dairy cows. These advancements are not only enhancing animal welfare but are also promoting more sustainable dairy farming by lowering antibiotic reliance.

The market is segmented into pharmaceutical products and supplements. The pharmaceutical segment generated USD 925.4 million in 2023, fueled by the growing incidence of udder infections and heightened concerns over antimicrobial resistance. The rising adoption of AI-powered prescription systems is enhancing treatment precision and herd health, further supporting growth in the pharmaceutical sector.

In terms of animal type, dairy cattle dominated the market with an 85.4% share in 2024. Rising investments in early diagnostic technologies, genetics, and disease resistance are reshaping herd management practices. Farmers are increasingly adopting probiotics and immunotherapy drugs amid global antibiotic restrictions, with AI-driven monitoring and automated milking systems gaining traction.

North America Udder Health Market accounted for 41% of global revenue in 2024 and is projected to grow at a CAGR of 5.8% from 2025 to 2034. Strong milk production across the U.S. is fueling the demand for advanced udder health solutions, including precision tools and sustainable management strategies. Regulatory pushes to reduce antibiotic use, led by the FDA and USDA, are further boosting the uptake of vaccines, probiotics, and immune-stimulant therapies.

Major players in the global udder health industry include Merck, BouMatic, AHV International, Albert Kerbl, Boehringer Ingelheim, Ceva Sante Animale, Ecolab, Elanco Animal Health, DeLaval, G Shepherd Animal Health, Virbac, and Zoetis. These companies are investing in innovative treatments to address antimicrobial resistance concerns, expanding AI and automation capabilities for diagnostics, partnering with veterinary clinics and farmers to improve product adoption, and enhancing sustainability efforts through eco-friendly product development and farmer education initiatives.

Table of Contents

Chapter 1 Methodology and Scope

• 1.1 Market scope and definitions
• 1.2 Research design
  • 1.2.1 Research approach
  • 1.2.2 Data collection methods
• 1.3 Base estimates and calculations
  • 1.3.1 Base year calculation
  • 1.3.2 Key trends for market estimation
• 1.4 Forecast model
• 1.5 Primary research and validation
  • 1.5.1 Primary sources
  • 1.5.2 Data mining sources

Chapter 2 Executive Summary

• 2.1 Industry 360⁰ synopsis

Chapter 3 Industry Insights

• 3.1 Industry ecosystem analysis
• 3.2 Industry impact forces
  • 3.2.1 Growth drivers
    • 3.2.1.1 Rising dairy consumption and production globally
    • 3.2.1.2 Increased awareness about udder health management
    • 3.2.1.3 Advancements in veterinary diagnostics and treatment
  • 3.2.2 Industry pitfalls and challenges
    • 3.2.2.1 Stringent regulations on antibiotic use in dairy industry
    • 3.2.2.2 High cost of udder health treatments and diagnostics
• 3.3 Growth potential analysis
• 3.4 Regulatory landscape
• 3.5 Trump administration tariffs
  • 3.5.1 Impact on trade
    • 3.5.1.1 Trade volume disruptions
    • 3.5.1.2 Retaliatory measures
  • 3.5.2 Impact on the Industry
    • 3.5.2.1 Supply-side impact (raw materials)
      • 3.5.2.1.1 Price volatility in key materials
      • 3.5.2.1.2 Supply chain restructuring
      • 3.5.2.1.3 Production cost implications
    • 3.5.2.2 Demand-side impact (selling price)
      • 3.5.2.2.1 Price transmission to end markets
      • 3.5.2.2.2 Market share dynamics
      • 3.5.2.2.3 Consumer response patterns
  • 3.5.3 Key companies impacted
  • 3.5.4 Strategic industry responses
    • 3.5.4.1 Supply chain reconfiguration
    • 3.5.4.2 Pricing and product strategies
    • 3.5.4.3 Policy engagement
  • 3.5.5 Outlook and future considerations
• 3.6 Porter's analysis
• 3.7 PESTEL analysis

Chapter 4 Competitive Landscape, 2024

• 4.1 Introduction
• 4.2 Company matrix analysis
• 4.3 Company market share analysis
• 4.4 Competitive analysis of major market players
• 4.5 Competitive positioning matrix
• 4.6 Strategy dashboard

Chapter 5 Market Estimates and Forecast, By Product Type, 2021-2034 ($ Mn)

• 5.1 Key trends
• 5.2 Pharmaceuticals
  • 5.2.1 Antibiotics
  • 5.2.2 Vaccines
  • 5.2.3 Anti-inflammatory drugs
  • 5.2.4 Teat disinfectants
  • 5.2.5 Intramammary infusions
  • 5.2.6 Other pharmaceuticals
• 5.3 Supplement
  • 5.3.1 Vitamins and minerals
  • 5.3.2 Probiotics and prebiotics
  • 5.3.3 Other supplements

Chapter 6 Market Estimates and Forecast, By Animal Type, 2021-2034 ($ Mn)

• 6.1 Key trends
• 6.2 Dairy cattle
• 6.3 Other animal types

Chapter 7 Market Estimates and Forecast, By Disease Type, 2021-2034 ($ Mn)

• 7.1 Key trends
• 7.2 Mastitis
  • 7.2.1 Clinical mastitis
  • 7.2.2 Sub-clinical mastitis
• 7.3 Other disease types

Chapter 8 Market Estimates and Forecast, By Distribution Channel, 2021-2034 ($ Mn)

• 8.1 Key trends
• 8.2 Veterinary hospital pharmacies
• 8.3 Retail pharmacies
• 8.4 Other distribution channels

Chapter 9 Market Estimates and Forecast, By Region, 2021-2034 ($ Mn)

• 9.1 Key trends
• 9.2 North America
  • 9.2.1 U.S.
  • 9.2.2 Canada
• 9.3 Europe
  • 9.3.1 Germany
  • 9.3.2 UK
  • 9.3.3 France
  • 9.3.4 Spain
  • 9.3.5 Italy
  • 9.3.6 Netherlands
• 9.4 Asia Pacific
  • 9.4.1 China
  • 9.4.2 Japan
  • 9.4.3 India
  • 9.4.4 Australia
  • 9.4.5 South Korea
• 9.5 Latin America
  • 9.5.1 Brazil
  • 9.5.2 Mexico
  • 9.5.3 Argentina
• 9.6 Middle East and Africa
  • 9.6.1 South Africa
  • 9.6.2 Saudi Arabia
  • 9.6.3 UAE

Chapter 10 Company Profiles

• 10.1 AHV International
• 10.2 Albert Kerbl
• 10.3 Boehringer Ingelheim
• 10.4 BouMatic
• 10.5 Ceva Sante Animale
• 10.6 DeLaval
• 10.7 Ecolab
• 10.8 Elanco Animal Health
• 10.9 G Shepherd Animal Health
• 10.10 Merck
• 10.11 Virbac
• 10.12 Zoetis